Human-relevant tissue,
by design.
By integrating micro-/nano-fabrication with stem cell biology, we develop iPSC-derived organoids and 3D tissue platforms, delivering a next-generation foundation for disease modeling and drug evaluation.
About Us
Amid a global shift away from reliance on animal testing, we design and deliver tissue models that are closer to human biology.
Aligned with regulation
We support the shift toward reduced reliance on animal models, in line with evolving global regulatory trends including FDA initiatives.
Convergence of technologies
By combining micro-/nano-fabrication with stem cell biology, we develop advanced human-relevant tissue and organoid systems.
iPSC organoids
Our proprietary iPSC-derived organoid platform enables disease modeling and drug evaluation.
Technology
From cardiac tissue maturation to functional assessment and cellular analysis — our proprietary technologies create tissue models that closely reflect human biology.
Cardiac maturation via self-sustained traveling waves
Using a self-generated traveling-wave mechanism that requires no external pacemaker, we functionally train immature iPSC-derived cardiomyocytes, promoting their electrophysiological and mechanical maturation.
Functional assessment
With a dual excitation-contraction recording system, we simultaneously capture the electrophysiological and mechanical responses of cardiac tissue, enabling precise evaluation of function and drug response.
Cellular evaluation
Combining Raman spectroscopy, molecular biology techniques, and other advanced analytical methods, we comprehensively assess cellular function, physiological state, and resistance to stress or injury. Integrating AI-driven data analysis, we provide detailed and actionable evaluation reports on cell quality, functionality, and therapeutic potential.
Company Profile
- Company name
- EngiTissue Design Co., Ltd.
- Founded
- December 26, 2024
- Head office
- Techno Alliance Building C, 2-8 Yamadaoka, Suita, Osaka 565-0871, Japan
- Laboratory
- Room 319, Photonics Center (P3), 2-1 Yamadaoka, Suita, Osaka 565-0871, Japan
- Business
- Design and manufacturing of iPSC-derived organoids
- Development of 3D tissue platforms for disease modeling and drug screening
- Cardiac tissue chips for cardiotoxicity and drug efficacy assessment
- Technology development and collaborative research support in tissue engineering
- Key customers
- Universities and public research institutions
- Pharmaceutical and biotechnology companies
- Contract research organizations (CROs)
- Capital
- 100 million JPY
Contact
We welcome inquiries about collaborative research, contract services, and our technologies. Please feel free to reach out.
Get in touch
You can contact us by email below. We can also set up a dedicated inquiry form upon request.
Email us →
